Cancer driver mutations are responsible for oncogenesis, and many tumors have recurrent somatic mutations in the PI3K-AKT1-mTOR signaling pathways [9,55,56,57], making these PI3K signaling genes good candidates for cancer therapy [57,58,59,60,61,62,63,64,65,66,67,68,69,70]. This evidence concerns the gene PIK3CA and cancer.